From the FDA Drug Label
The FDA drug label does not answer the question.
From the Research
Trimethylglycine (TMG) supplementation is recommended to support homocysteine management, with a suggested dose of 500-1000mg daily, divided into 1-2 doses with meals, based on the most recent and highest quality study available 1. For specific health concerns like homocysteine management, doses up to 3000mg daily (divided into three 1000mg doses) may be appropriate. TMG works primarily as a methyl donor in the body, helping convert homocysteine back to methionine through a process called methylation. This is particularly important for cardiovascular health, as elevated homocysteine levels are associated with increased risk of heart disease, as suggested by a Mendelian randomization study 2.
Some key points to consider when supplementing with TMG include:
- Starting with lower doses and increasing gradually to assess tolerance, as some people may experience minor digestive discomfort.
- TMG is generally well-tolerated, but those with existing medical conditions should consult a healthcare provider before beginning supplementation.
- The combination of TMG with other supplements like folic acid, vitamin B6, and vitamin B12 may have synergistic effects on homocysteine levels, as observed in a study on the effect of these supplements on homocysteine and dimethylglycine levels in middle-aged men drinking white wine 3.
- The link between homocysteine, folic acid, and vitamin B12 in chronic kidney disease is an area of ongoing research, with some studies suggesting that supplementation with these vitamins may be beneficial in reducing homocysteine levels and cardiovascular risk 4.
Overall, the current evidence suggests that TMG supplementation can be a useful adjunct in managing homocysteine levels and supporting cardiovascular health, particularly when used in conjunction with other supplements like folic acid, vitamin B6, and vitamin B12, as supported by a systematic review on the impact of supplementation with these vitamins on homocysteine levels in patients with mild cognitive impairment 1.